Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for a wide range of diseases including eye conditions, cancer, and inflammatory disorders. Their key products include EYLEA, Dupixent, Libtayo, Praluent, and Kevzara, targeting significant unmet medical needs. Regeneron holds a strong market position through its innovative therapies and strategic collaborations.
AI-generated summary. Not investment advice.